NASDAQ:SVRASavara Stock Price, Forecast & News

$2.42

-0.02 (-0.82 %)

(As of 06/2/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.38

Now: $2.42▼

$2.50

50-Day Range

$2.12

MA: $2.38▼

$2.56

52-Week Range

$0.69

Now: $2.42▼

$11.39

Volume387,800 shs

Average Volume440,324 shs

Market Capitalization$126.29 million

P/E RatioN/A

Dividend YieldN/A

Beta0.92

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Savara has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.32, Savara has a potential upside of 243.8% from its current price of $2.42.
Amount of Analyst Coverage
Savara has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Savara has received 259 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Savara has received 280 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Savara has received 51.95% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote “Outperform” if you believe SVRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Savara does not currently pay a dividend.
Dividend Growth
Savara does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Savara insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.77% of the stock of Savara is held by insiders.
Percentage Held by Institutions
46.02% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Savara are expected to grow in the coming year, from ($1.04) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Savara is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Savara is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Savara has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.59 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SVRA

Previous SymbolAMEX:ANX

CUSIPN/A

CIK1160308

Webwww.savarapharma.com

Phone512-614-1848

Debt

Debt-to-Equity Ratio0.28

Current Ratio13.90

Quick Ratio13.90

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash Flow$5.04 per share

Price / Cash Flow0.48

Book Value$2.47 per share

Price / Book0.98

Profitability

EPS (Most Recent Fiscal Year)$4.57

Net Income$-78,170,000.00

Net MarginsN/A

Return on Equity-53.48%

Return on Assets-40.16%

Miscellaneous

EmployeesN/A

Outstanding Shares52,187,000

Market Cap$126.29 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Savara (NASDAQ:SVRA) Frequently Asked Questions

How has Savara's stock been impacted by COVID-19 (Coronavirus)?

Savara's stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SVRA stock has increased by 2.5% and is now trading at $2.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Savara?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Savara.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Savara.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) posted its earnings results on Thursday, May, 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.01. View Savara's earnings history.

What price target have analysts set for SVRA?

5 analysts have issued 12-month price objectives for Savara's shares. Their forecasts range from $1.00 to $17.00. On average, they anticipate Savara's share price to reach $8.32 in the next twelve months. This suggests a possible upside of 243.8% from the stock's current price. View analysts' price targets for Savara.

Has Savara been receiving favorable news coverage?

Media coverage about SVRA stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Savara earned a news impact score of -3.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutSavara.

Who are some of Savara's key competitors?

Some companies that are related to Savara include VBI Vaccines (VBIV), Urogen Pharma (URGN), Emisphere Technologies (EMIS), DURECT (DRRX), Xenon Pharmaceuticals (XENE), BioDelivery Sciences International (BDSI), Beyondspring (BYSI), Neoleukin Therapeutics (NLTX), Fulcrum Therapeutics (FULC), Satsuma Pharmaceuticals (STSA), Protagonist Therapeutics (PTGX), Prothena (PRTA), Syros Pharmaceuticals (SYRS), Catalyst Pharmaceuticals (CPRX) and RAPT Therapeutics (RAPT). View all competitors.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BIOLINERX LTD/S (BLRX), CEL-SCI (CVM), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Gilead Sciences (GILD), Myovant Sciences (MYOV), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are Savara's key executives?

Savara's management team includes the following people:

Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
David L. Lowrance, Chief Financial Officer (Age 50)
Nevan C. Elam, Independent Director (Age 49)
Richard J. Hawkins, Independent Director (Age 68)
Joseph S. McCracken Ph.D., Independent Director (Age 64)
Matthew Pauls J.D., Independent Director (Age 46)
Yuri Pikover, Independent Director (Age 56)

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.52%), AXA (2.57%), State Street Corp (1.06%), Geode Capital Management LLC (0.92%), Acadian Asset Management LLC (0.43%) and Dupont Capital Management Corp (0.22%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins and Robert N Neville. View institutional ownership trends for Savara.

Which major investors are selling Savara stock?

SVRA stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Deutsche Bank AG, and UBS Group AG. View insider buying and selling activity for Savara.

Which major investors are buying Savara stock?

SVRA stock was purchased by a variety of institutional investors in the last quarter, including AXA, Acadian Asset Management LLC, Dupont Capital Management Corp, Geode Capital Management LLC, Intellectus Partners LLC, BlackRock Inc., SG Americas Securities LLC, and Bank of New York Mellon Corp. Company insiders that have bought Savara stock in the last two years include David A Ramsay, and Robert N Neville. View insider buying and selling activity for Savara.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $2.42.

How big of a company is Savara?

Savara has a market capitalization of $126.29 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.

What is Savara's official website?

The official website for Savara is www.savarapharma.com.

How can I contact Savara?

Savara's mailing address is 900 S. CAPITAL OF TEXAS HIGHWAY SUITE 150, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff